Literature DB >> 26488701

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Akihiko Ozaki, Tetsuya Tanimoto, Shigehira Saji.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26488701     DOI： 10.1056/NEJMc1510345

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.

Authors:  Se Jin Oh; Hanbyoul Cho; Suyeon Kim; Suhyun Kim; Kyung Hee Noh; Kwon-Ho Song; Hyo-Jung Lee; Seon Rang Woo; Chel Hun Choi; Joon-Yong Chung; Stephen M Hewitt; Jae-Hoon Kim; Seungki Baek; Kyung-Mi Lee; Cassian Yee; Hae-Chul Park; Tae Woo Kim
Journal:  Cancer Res       Date:  2018-02-06       Impact factor: 12.701

2.  Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.

Authors:  Xiaoyang Li; Nicole A Seebacher; Cassandra Garbutt; Hangzhan Ma; Peng Gao; Tao Xiao; Francis J Hornicek; Zhenfeng Duan
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

3.  Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.

Authors:  Barbara Adamo; Meritxell Bellet; Laia Paré; Tomás Pascual; Maria Vidal; José A Pérez Fidalgo; Salvador Blanch; Noelia Martinez; Laura Murillo; Patricia Gómez-Pardo; Ana López-González; Kepa Amillano; Jordi Canes; Patricia Galván; Blanca González-Farré; Xavier González; Patricia Villagrasa; Eva Ciruelos; Aleix Prat
Journal:  Breast Cancer Res       Date:  2019-09-18       Impact factor: 6.466

4.  Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.

Authors:  Jianliang Xu; Fei Huang; Zhicheng Yao; Changchang Jia; Zhiyong Xiong; Hao Liang; Nan Lin; Meihai Deng
Journal:  Cell Commun Signal       Date:  2019-07-26       Impact factor: 5.712

5.  CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer.

Authors:  Xiaoye Sang; Nassira Belmessabih; Ruixuan Wang; Preyesh Stephen; Sheng-Xiang Lin
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

Review 6.  Heterogeneity in Cancer Metabolism: New Concepts in an Old Field.

Authors:  Géraldine Gentric; Virginie Mieulet; Fatima Mechta-Grigoriou
Journal:  Antioxid Redox Signal       Date:  2016-07-13       Impact factor: 8.401
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.